Efficacy of orally administered combination of moxidectin, sarolaner and pyrantel (Simparica Trio™) for the prevention of experimental Angiostrongylus vasorum infection in dogs

Table 4 Studies 2 and 3: Angiostrongylus vasorum L1 counts in the feces and lung, percent efficacy, mean percent consolidated lung lobe area and mean total lung lesion severity scores by treatment group

Study	Group^a	Fecal L1 counts^b		Lung L1 counts		Lung lesions^c
Study	Group^a	Geometric mean	% Efficacy	Geometric mean	% Efficacy	% Lung consolidation	Mean total severity score
Study 2	Placebo	2.349	–	157.4	–	54.5	11.3
Study 2	Simparica Trio™	0	100	0.0	100	1.9	2.7
Study 3	Placebo	3.793	–	336.2	–	59.0	12.0
Study 3	Simparica Trio™	0.050	98.7	1.9	99.4	1.2	0.9

^aThe Simparica Trio™-treated dogs received 24 µg/kg moxidectin, 1.2 mg/kg sarolaner and 5 mg/kg pyrantel
^bFecal L1 counts (per gram feces) were conducted daily on samples collected before necropsy for 3 days
^cAt necropsy the percentage of consolidation for each of the six lung lobes was assessed and the mean % consolidation was calculated. The severity of the lesions on each lobe was scored on a scale from 0 to 3 (the maximum possible total score was 18)

ISSN: 1756-3305